Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Actavis’ Record-Breaking Quarterly Sales Show Success Of Merger Strategy

This article was originally published in The Pink Sheet Daily

Executive Summary

Strong quarter for generic Mycardis, Lidoderm and Cymbalta spurs 36% increase in pharma product sales, while businesses inherited from Warner Chilcott lead to exponential growth in North American branded product revenue. Firm is getting ready for integration of Forest around mid-year.


Related Content

Watson Begins Anew As Actavis, Focuses On Organic Growth


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts